Imperial College London
Portrait Picture

Dr Joseph van Batenburg-Sherwood

Faculty of Engineering, Department of Bioengineering

Lecturer
 
 
 
//

Contact

 

+44 (0)20 7594 7244jvbsherwood Website

 
 
//

Location

 

Uren 416ASir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{O'Callaghan:2023:10.1126/sciadv.adf6537,
author = {O'Callaghan, J and Delaney, C and O'Connor, M and van, Batenburg-Sherwood J and Schicht, M and Lütjen-Drecoll, E and Hudson, N and Ni, Dhubhghaill S and Humphries, P and Stanley, C and Keravala, A and Chalberg, T and Lawrence, MS and Campbell, M},
doi = {10.1126/sciadv.adf6537},
journal = {Science Advances},
pages = {1--14},
title = {Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma.},
url = {http://dx.doi.org/10.1126/sciadv.adf6537},
volume = {9},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision loss. The major risk factor for glaucoma is elevated intraocular pressure, which is regulated by the balance between the secretion of aqueous humor and the resistance to its flow across the conventional outflow pathway. Here, we show that adeno-associated virus 9 (AAV9)-mediated expression of matrix metalloproteinase-3 (MMP-3) can increase outflow in two murine models of glaucoma and in nonhuman primates. We show that long-term AAV9 transduction of the corneal endothelium in the nonhuman primate is safe and well tolerated. Last, MMP-3 increases outflow in donor human eyes. Collectively, our data suggest that glaucoma can be readily treated with gene therapy-based methods, paving the way for deployment in clinical trials.
AU  - O'Callaghan,J
AU  - Delaney,C
AU  - O'Connor,M
AU  - van,Batenburg-Sherwood J
AU  - Schicht,M
AU  - Lütjen-Drecoll,E
AU  - Hudson,N
AU  - Ni,Dhubhghaill S
AU  - Humphries,P
AU  - Stanley,C
AU  - Keravala,A
AU  - Chalberg,T
AU  - Lawrence,MS
AU  - Campbell,M
DO  - 10.1126/sciadv.adf6537
EP  - 14
PY  - 2023///
SN  - 2375-2548
SP  - 1
TI  - Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma.
T2  - Science Advances
UR  - http://dx.doi.org/10.1126/sciadv.adf6537
UR  - https://www.ncbi.nlm.nih.gov/pubmed/37075118
UR  - https://www.science.org/doi/10.1126/sciadv.adf6537
UR  - http://hdl.handle.net/10044/1/104430
VL  - 9
ER  -
Download